DCM
CERO

Difesa Capital Management’s CERo Therapeutics CERO Stock Holding History

Difesa Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-63
Closed -$1.29M – 215
2022
Q4 		$1.29M Buy
+63
New +$1.28M 1% 48

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Difesa Capital Management's CERO Position: Q1 2023 in Review

Difesa Capital Management sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 63 shares — an estimated $1.29M sold.

Difesa Capital Management first reported a position in CERO in Q4 2022 and held it in 1 quarter. The position peaked at $1.29M in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • Difesa Capital Management reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Difesa Capital Management sold 63 CERo Therapeutics shares in Q1 2023, an estimated $1.29M.
  • Difesa Capital Management first reported a position in CERo Therapeutics in Q4 2022 and held it in 1 quarter.
  • Difesa Capital Management's CERo Therapeutics position peaked at $1.29M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on Difesa Capital Management's 13F filing for Q1 2023, filed 15 May 2023.